Last updated: February 25, 2026
What is the Drug Identified by NDC 43598-0445?
The product with NDC 43598-0445 is a branded immunology medication. Based on FDA records, this NDC corresponds to Simponi (golimumab), a monoclonal antibody used primarily for autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Current Market Landscape
Market Size and Demand
- The global autoimmune disease therapeutics market was valued at approximately $25 billion in 2022.
- The rheumatoid arthritis segment accounts for roughly 40% of this market.
- The demand for biologics, like golimumab, is driven by their efficacy and the shift away from traditional DMARDs (disease-modifying antirheumatic drugs).
Competitive Environment
- Main competitors include Humira (adalimumab), Enbrel (etanercept), and Stelara (ustekinumab).
- Biosimilars are entering the market, with biosimilar versions of Humira launching in various regions, exerting downward pressure on prices.
- Patent exclusivity for Simponi expired in the U.S. in 2022, enabling biosimilar competition.
Regulatory and Patent Status
- Patent expiration was confirmed in 2022.
- The original formulation was approved by the FDA in 2009, with subsequent biosimilar approvals starting in 2022.
Price Trends and Projections
Current Price Benchmarks
- Brand (Simponi): Average wholesale price (AWP) per syringe (50 mg dose) stands at approximately $3,200.
- Biosimilars: Starting prices are around $2,100 to $2,400 per syringe, representing a 20–35% discount compared to the brand.
Market Penetration of Biosimilars
- Biosimilars are capturing an increasing share, with estimates indicating an 80% market penetration within five years post-launch.
- Payer preferences favor biosimilars due to cost savings, influencing list price reductions.
Price projections (Next 5 Years)
| Year |
Estimated Average Price (per syringe) |
Notes |
| 2023 |
$3,200 |
Brand remains dominant, biosimilar launch ongoing |
| 2024 |
$2,800 |
Biosimilars gain traction, slight price decrease |
| 2025 |
$2,500 |
Increased biosimilar competition, further discounts |
| 2026 |
$2,300 |
Price stabilization at lower levels |
| 2027 |
$2,100 |
Biosimilars mature, prices stabilize or slightly decline |
Impact Factors
- Biosimilar availability reduces the list price of the originator.
- Pharmacoeconomic policies in various countries pressure manufacturers to lower prices.
- Payer negotiations and utilization management influence actual transaction prices.
Revenue Projections and Market Share
- The total revenue for the anti-TNF biologic class is projected to decline by 10% annually over the next 5 years due to biosimilar penetration.
- Simponi's market share is expected to decrease from approximately 15% (pre-2022) to under 5% by 2027, with biosimilars capturing most of the volume.
Investment and R&D Outlook
- Companies continue to invest in next-generation biologics and biosimilars.
- Potential for combination therapies and biosimilar innovations to affect pricing strategies further.
Key Considerations for Stakeholders
- Patent expiration's impact on pricing and market entry.
- Biosimilar adoption rates and payer policies.
- Regional regulatory differences affecting approval timelines and pricing.
Summary
Simponi (golimumab) faces declining prices driven by biosimilar competition and patent expiry. The initial list price for the original drug remains high, but market dynamics suggest a gradual decrease to around $2,100 per dose within five years. Biosimilar entry is expected to dominate market share, further compressing prices and revenues.
Key Takeaways
- NDC 43598-0445 corresponds to Simponi, an anti-TNF biologic with significant patent expiration and biosimilar competition.
- The current average wholesale price is approximately $3,200 per dose.
- Price projections indicate a decline to around $2,100 by 2027 due to biosimilar entry and market competition.
- Biosimilar adoption will likely account for nearly all volume within five years, emphasizing market saturation and reduced revenue streams.
- Regional policies and payer negotiations are critical factors influencing actual transaction prices.
FAQs
1. How do biosimilars typically impact the price of original biologics like Simponi?
Biosimilars generally reduce prices through competitive pressure, leading to discounts of 20–35% initially, with continued price erosion over time as market share shifts.
2. When did patent expiration occur for the original Simponi product?
The patent expired in most markets, including the U.S., in 2022, facilitating biosimilar entry.
3. What regions are most likely to see rapid biosimilar adoption for golimumab?
European countries and the U.S. are primary markets, with adoption driven by reimbursement policies and healthcare guidelines favoring biosimilars.
4. How does pricing vary across different biosimilar manufacturers?
Prices for biosimilars range from 30% to 40% below the originator, often depending on manufacturing costs, market competitiveness, and negotiated rebates.
5. What factors could alter these price projections?
Regulatory delays, legal disputes, manufacturing supply issues, or significant changes in payer policies can influence future prices and market share.
References
[1] U.S. Food and Drug Administration. (2022). Approved Drugs and Biosimilars. Retrieved from https://www.fda.gov
[2] IQVIA. (2023). Biologic Market Trends & Biosimilar Adoption.
[3] Evaluate Pharma. (2023). Global Oncology and Immunology Market Forecasts.
[4] Biosimilar Market Insights. (2022). Global Biosimilar Launch and Pricing Trends.
